Population-based cross-sectional study of 11 645 Spanish nonagenarians with type 2 diabetes mellitus: cardiovascular profile, cardiovascular preventive therapies, achievement goals and sex differences

Miguel Angel Salinero-Fort, Jose M Mostaza-Prieto, Carlos Lahoz-Rallo, José Ignacio Vicente Díez, Juan Cárdenas-Valladolid

ABSTRACT

Objectives To evaluate the risk profile, achievement of cardiometabolic goals, and frequency and optimal use of cardiovascular preventive therapies among nonagenarians with type 2 diabetes mellitus (T2DM). To investigate possible sex differences.

Design and setting A cross-sectional population study of 11 645 persons aged ≥90 years with T2DM living in Madrid (Spain). Sociodemographic, clinical and therapy profiles were collected through electronic records in primary care. We considered antihypertensive therapy and lipid-lowering therapy to be optimal when known patients with hypertension with albuminuria received renin–angiotensin system blockers and statins had been prescribed for overt cardiovascular disease.

Results The prevalence of coronary artery disease was higher in males than in females (21.5% vs 12.6%, p<0.01), as was that of peripheral artery disease (8.5% vs 2.3%, p<0.01). However, the prevalence of cerebrovascular disease was similar in both sexes (16.5% vs 16%; p=0.44). Haemoglobin A1c was lower than 7% in 64.4% of cases, with female predominance in patients with known dementia (67.1% female vs 59.9% male; p<0.01). Antiplatelet therapy was significantly more frequent in males than in females (48.1% vs 44.3%; p<0.01), as were statins (43.2% vs 40.2%; p<0.01). Both in primary and in secondary prevention, rates for simultaneous achievement of the HbA1c, blood pressure, LDL-C goals were significantly lower among females (p<0.01). For each criterion of optimal use of cardiovascular preventive therapies, adherence was significantly better in males than in females.

Conclusion Our study showed that the risk of cerebrovascular disease was similar in both male and female Spanish nonagenarians. Adherence was poorer in females for all criteria of optimal use of cardiovascular preventive therapies. Our findings indicate that the known sex differences in younger patients with T2DM persist in patients aged ≥90 years. There is considerable room for improvement in standards of preventive care in nonagenarians with T2DM, especially in females.

Strengths and limitations of this study

- The strength of the study is based on the inclusion of all diabetic people of our region that avoids selection bias.
- The use of data on real-life clinical practice at the primary care level increases knowledge of different health workers and health political makers and confirms the possibility of improving the clinical management of patients and reorienting the clinical practice.
- The limitation of this study is that it is not possible to establish causal relationships between variables given its cross-sectional design.
- The study has an excessive number of missing data for some variables such as blood pressure, body mass index, estimated glomerular filtration rate, albumin, haemoglobin A1c, density lipoprotein cholesterol, low-density lipoprotein cholesterol and fasting plasma glucose.

INTRODUCTION

Between 2000 and 2015, global life expectancy experienced its fastest growth since the 1990s, increasing by 5 years, according to WHO. Older people have a high risk of developing coronary artery disease, cerebrovascular disease and peripheral artery disease, and cardiovascular disease is the leading cause of death in this age group. In addition, the prevalence of type 2 diabetes mellitus (T2DM) increases with age, and poor glycaemic control may worsen cardiovascular risk and accelerate the cognitive aging process.

However, evidence remains limited regarding the use of drugs for primary prevention in persons with diabetes aged >75 years. This group is not included in the...
American College of Cardiology/American Heart Association guidelines. Single use of drugs such as statins has been reported in elderly patients with symptomatic atherosclerosis. Furthermore, the Screening Tool of Older Persons’ potentially inappropriate Prescriptions (STOPP) criteria do not recommend that elderly patients discontinue statins.  

The multiple factors that have to be considered when prescribing for elderly patients include frailty, comorbidities, the patient’s own wishes regarding the goals of therapy, pharmacodynamic and pharmacokinetic changes associated with ageing (eg, decreased gastrointestinal absorption, reduced renal and hepatic clearance, lower lean muscle mass), polypharmacy, cost of therapy and the risk for drug–drug interactions. Other variables such as sex may also affect prescription, as previously reported in patients with diabetes. 

Data on the management of very aged patients with T2DM are scarce. This is particularly true for cardiovascular drugs. 

In the present study, we evaluated risk profile, achievement of cardiometabolic goals, and frequency and pattern of use of evidence-based cardiovascular preventive therapies in persons with T2DM aged ≥90 years in the Community of Madrid (Spain). We also studied sex differences in the prevalence of cardiovascular diseases and cardiovascular risk factors.

PATIENTS AND METHODS

Study design

We performed a population-based, cross-sectional study of all residents aged ≥90 years living in the Community of Madrid (Spain). The Community of Madrid is a public entity providing healthcare coverage to 100% of the population. It provides primary care through 3881 general practitioners working in 265 health centres. All residents have an electronic clinical record in primary care. The record constitutes a clinical database of anonymised data. As at 31 December 2015, it contained data for 61 059 persons aged ≥90 years. Data were available for 59 423 subjects, of whom 11 645 were diagnosed with T2DM. In order to avoid selection bias, we analysed all subjects with T2DM.

Variables and definitions

Data for all participants (n=11 645) were collected through electronic clinical records in primary care. We included age, sex, cardiovascular risk factors, comorbidities and medication prescriptions as at 31 December 2015. Comorbidities were recorded according to the International Classification of Primary Care-Second Edition (ICPC-2).

The most recent blood analysis was recorded only if it was performed during 2014 or 2015. Data on low-density lipoprotein cholesterol (LDL-C) were available for 8167 subjects. Similarly, anthropometric measurements, smoking history, basic and instrumental activities of daily life, and blood pressure were only collected if obtained during the 2 years before data collection. Smoking status was available for 7512 subjects, basic and instrumental activities of daily life for 5631 and 5582, respectively, and blood pressure for 8455.

Basic and instrumental activities of daily life were measured using the Barthel Index and Lawton and Brody Index, respectively. The Charlson Index, which predicts 10-year mortality according to a wide range of comorbid conditions (eg, age, diabetes with or without organ damage, liver disease, chronic kidney disease, AIDS, malignancy, congestive heart failure, previous acute myocardial infarction, chronic obstructive pulmonary disease (COPD), peripheral vascular disease, transient ischaemic attack or stroke, dementia, haemiplegia, connective tissue disease and peptic ulcer disease), was calculated for all participants.

We recorded the percentage of patients with the following analytical values: haemoglobin A1c (HbA1c) <7.0% and <8.0%; blood pressure <130/80 mm Hg; <140/85 mm Hg and <140/90 mm Hg; LDL-C <130 mg/dL (3.4 mmol/L) <100 mg/dL (2.6 mmol/L) and <70 mg/dL (1.81 mmol/L); and the composite endpoint of HbA1c <7.0%, blood pressure <140/85 mm Hg and LDL-C <100 mg/dL (2.6 mmol/L).

Cardiovascular disease was defined as a previous diagnosis of angina pectoris, myocardial infarction, stroke or peripheral artery disease in the electronic clinical record (ICPC-2 codes K74, K75, K76, K90 and K92). Dementia was identified by the P70 code of ICPC-2.

We considered antihypertensive therapy to be optimal when known hypertensive patients with albuminuria received ACE inhibitors or angiotensin II receptor blockers (ARBs). We considered lipid-lowering therapy to be optimal when statins had been prescribed for overt cardiovascular disease. We considered the use of statins for primary prevention not clearly indicated, as this practice derives mainly from subgroup analyses and post hoc data of studies that do not include nonagenarians.

Antithrombotic therapy was labelled as optimal when antiplatelet drugs or anticoagulants had been prescribed for pre-existing cardiovascular disease or chronic atrial fibrillation in the absence of contraindications. The use of antiplatelet medication for primary prevention was, therefore, not considered optimal treatment.

The quality of the primary care electronic clinical record for research use has previously been validated and the database has been widely used to study the epidemiology of cardiovascular risk factors in the study population.

Statistical analysis

Continuous variables are presented as mean (SD), and categorical variables as percentages. Continuous variables were compared using the t-test, and categorical variables were compared using the χ² test. Effect sizes were calculated using Cohen’s d for continuous measures and Cramer’s V for categorical variables. The magnitude of
difference was classified as small if the value of Cohen’s d ranged from 0.2 to 0.5, as moderate if it ranged from 0.5 to 0.8 or, as large if Cohen’s d value was greater than 0.8. Logistic regression analyses were performed in order to evaluate the independent contribution of different variables to the adequacy of prescription of statins.

Data were processed using SPSS for Windows, V.19.0 (IBM).

**Patient and public involvement**

No patient involved.

**RESULTS**

Of a total population of 59423 individuals aged ≥90 years and resident in Madrid as at 31 December 2015, 11 645 people were diagnosed with T2DM, that is, a prevalence of 19.6% (20.4% in males and 19.3% in females; p<0.01). All of these patients were included in the study. Mean age was 92.9 (2.5) years, 73.1% were females and 13.6% were living in a nursing home. There were 175 subjects (1.5%) aged ≥100 years.

Cardiovascular disease was present in 3602 subjects (30.9%); only 1 vascular territory was involved in 27% and ≥2 in 3.9%. The global prevalence of cardiovascular disease was higher in males than in females (39.5% vs 27.8%, p<0.01), as was the prevalence of coronary artery disease and peripheral artery disease (21.5% vs 12.6% (p<0.01) and 8.5% vs 2.3% (p<0.01); respectively). However, the prevalence of cerebrovascular disease was similar in both sexes (16.5% vs 16%; p=0.44).

The clinical characteristics of the population are shown in table 1. Male subjects had a higher prevalence of chronic atrial fibration, current smoking, chronic kidney disease, albuminuria and other comorbidities (ie, solid organ cancer, COPD). They also had a lower prevalence of dependence and dementia, and, consequently, a lower proportion were living in a nursing home than female subjects (9.1% vs 15.3%; p<0.01).

Females had a significantly higher prevalence of cardiovascular risk factors such as hypertension, dyslipidaemia and obesity. They also had significantly higher values of systolic blood pressure, diastolic blood pressure and body mass index than males, irrespective of whether they lived in nursing homes or in their own homes.

As for laboratory parameters, females had significantly worse values in total cholesterol, LDL-C, triglycerides, albumin and estimated glomerular filtration rate.

With respect to cardiovascular preventive therapies, nearly half of the patients were taking antiplatelet agents, which were significantly more common in males (48.1% vs 44.3%; p=0.01), as were statins (43.2% vs 40.2%; p<0.01). Of 8043 people free of cardiovascular events (primary prevention), 2795 (34.8%) were taking statins and 22.4% (n=627) had no previous known LDL-C value (figure 1). Of the 3602 patients in secondary prevention, 1981 (55%) were taking statins, and 23.8% (n=472) had no known LDL-C value (figure 2). Therefore, regardless of the type of prevention, approximately a quarter of the diabetic nonagenarians who received statins had no follow-up of their lipid levels.

T2DM was managed exclusively with dietary and lifestyle changes in 24.7% of patients; the finding was significantly higher in females than in males (25.2% vs 23.4%; p<0.01). Use of insulin alone was more common in females, and insulin combined with oral glucose-lowering drugs was more frequent in males. Oral glucose-lowering drugs alone were more common in males (54.7% vs 51.4%; p<0.01).

The achievement goals are summarised in table 2. Briefly, approximately one-third of the patients (31.6%) had no HbA1c value recorded in their electronic clinical record during the previous year. This figure was higher in patients with known dementia (36.4%). Of 7961 patients with recorded HbA1c values, a total of 5129 (64.4%) achieved HbA1c <7%. Sex differences were observed in patients with known dementia, namely, achievement was higher in females than in males (67.1% vs 59.9%; p<0.01). HbA1c <8% was observed in 6860 subjects (86.2%), with no sex differences. LDL-C values were available for 8167 patients (70.1%), of whom 4828 (59.1%) achieved LDL-C <100 mg/dL. Males attained better optimal control of LDL-C levels (<130, <100 and 70 mg/dL, respectively) than females, both in primary and secondary prevention. Of 8455 patients with blood pressure values available, 3118 (36.9%) achieved the optimal blood pressure target (<130/80 mm Hg) and 5521 (65.3%) a less strict target (<140/90 mm Hg). Except for the strictest control in secondary prevention (<130/80 mm Hg), optimal control of blood pressure was more common in males, both in primary and in secondary prevention. The ABC goal (A, HbA1c <7%; B, blood pressure <140/85 mm Hg; C, LDL-C <100 mg/dL) was reached by 10.6% of patients, although this percentage was higher in males than in females (13.4 vs 9.5%; p=0.01) and in secondary prevention with respect to primary prevention (12.4% vs 9.7%; p<0.01).

The prevalence of hypertension was 81.4% (n=9483), and 4632 patients were taking ACE inhibitors or ARBs (48.8%), that is, our optimal criteria for treatment of hypertension.

In secondary prevention, 24% of patients with lipid data available from the clinical history had LDL-C >130 mg/dL, and 34% were receiving statins, with no differences between the sexes. However, differences were observed in patients with no history of cardiovascular events, given that 21.3% of males received statins compared with 31% of women (p=0.02). After adjusting for sex, age and dementia, the factor most associated with adequate use of statins was a low Charlson Index (table 3).

Lastly, 5026 (43.2%) subjects had previously had cardiovascular events and/or chronic atrial fibrillation and, therefore, were candidates for antithrombotic treatment, which was prescribed appropriately in 86.3% of cases. Adherence was significantly better in males (table 4) for
### Table 1  
Sociodemographic, clinical characteristics, and therapeutic profile of 11,645 nonagenarian living with type 2 diabetes mellitus

|                                      | Available values, % | All            | Females        | Males          | P value | Effect size |
|--------------------------------------|---------------------|----------------|----------------|----------------|---------|-------------|
| No (%)                               | 100                 | 11,645         | 8,507 (73.1)   | 3,138 (26.9)   | –       | –           |
| Age (years), mean (SD)               | 100                 | 92.9 (2.5)     | 93 (2.6)       | 92.5 (2.2)     | <0.01   | 0.21*       |
| Living in a nursing home (%)         | 100                 | 1,587 (13.6)   | 1,301 (15.3)   | 286 (9.1)      | <0.01   | 0.08†       |
| Basic activities of daily living     | 48.4                |                |                |                |         |             |
| Barthel Index, mean (SD)             | 100                 | 61.5 (29.7)    | 58.8 (29.7)    | 68.7 (28.5)    | <0.01   | 0.34*       |
| Barthel Index categories             |                     |                |                |                |         |             |
| Functionally independent (%)         | 100                 | 562 (10)       | 324 (7.8)      | 238 (16)       | <0.01   | 0.16†       |
| Instrumental activities of daily living|                   | 47.9           |                |                |         |             |
| Lawton and Brody Index, mean (SD)    | 100                 | 3.6 (2.5)      | 3.4 (2.5)      | 3.8 (2.4)      | <0.01   | 0.16*       |
| Lawton and Brody categories (%)      |                     |                |                |                |         |             |
| Functionally independent (%)         | 100                 | 501 (9)        | 350 (8.6)      | 151 (10)       | <0.01   | 0.09†       |
| Smoking                              | 64.5                |                |                |                |         |             |
| Current smoker (%)                   | 100                 | 121 (1.6)      | 36 (0.7)       | 85 (4)         | <0.01   | 0.16†       |
| Former smoker (%)                    |                     | 97 (1.3)       | 27 (0.5)       | 70 (3.3)       |         |             |
| Never smoker (%)                     | 100                 | 7,294 (97.1)   | 5,325 (98.8)   | 1,969 (92.7)   |         |             |
| History of                           |                     |                |                |                |         |             |
| Hypertension (%)                     | 100                 | 9,483 (81.4)   | 7,204 (84.7)   | 2,279 (72.6)   | <0.01   | 0.14†       |
| Coronary artery disease (%)          | 100                 | 1,744 (15)     | 1,068 (12.6)   | 676 (21.5)     | <0.01   | 0.12†       |
| Myocardial infarction (%)            | 100                 | 786 (6.7)      | 438 (5.1)      | 348 (11.1)     | <0.01   | 0.11†       |
| Stroke (%)                           | 100                 | 1,876 (16.1)   | 1,357 (16)     | 519 (16.5)     | 0.44    | 0.01†       |
| Peripheral arterial disease (%)      | 100                 | 464 (4)        | 198 (2.3)      | 266 (8.5)      | <0.01   | 0.14†       |
| Heart failure (%)                    | 100                 | 1,706 (14.7)   | 1,266 (14.9)   | 440 (14)       | 0.24    | 0.01†       |
| Chronic atrial fibrillation (%)      | 100                 | 2,270 (19.5)   | 1,611 (18.9)   | 659 (21)       | 0.01    | 0.01†       |
| Dyslipidaemia (%)                    | 100                 | 5,500 (47.2)   | 4,207 (49.5)   | 1,293 (41.2)   | <0.01   | 0.07†       |
| Chronic kidney disease (%)           | 100                 | 1,876 (16.1)   | 1,290 (15.2)   | 586 (18.7)     | <0.01   | 0.04†       |
| Albuminuria (%)                      | 100                 | 1,625 (40.4)   | 1,085 (37.8)   | 540 (46.8)     | <0.01   | 0.08†       |
| Dementia (%)                         | 100                 | 1,550 (13.3)   | 1,255 (14.8)   | 295 (9.4)      | <0.01   | 0.07†       |
| Charlson Comorbidity Index, mean (SD)| 100                 | 7.37 (1.39)    | 7.30 (1.33)    | 7.57 (1.2)     | <0.01   | 0.10*       |
| Anthropometric variables             |                     |                |                |                |         |             |
| SBP (mm Hg), mean (SD)               | 100                 | 72.6           | 131.1 (17.1)   | 131.7 (17.2)   | <0.01   | 0.14*       |
| DBP (mm Hg), mean (SD)               | 100                 | 72.6           | 70.1 (8.5)     | 70.6 (9.5)     | <0.01   | 0.18*       |
| BMI (kg/m²), mean (SD)               | 100                 | 46.2           | 27 (4.5)       | 27.2 (4.8)     | <0.01   | 0.14*       |
| BMI categories                       | 46.2                |                |                |                |         |             |
| BMI <25 Kg/m², n (%)                 |                    | 1,824 (33.9)   | 1,243 (33.4)   | 581 (35)       | <0.01   | 0.10†       |
| BMI 25–29 Kg/m², n (%)               | 2317 (43.1)         | 1,515 (40.7)   | 802 (48.3)     |              |         |             |
| BMI ≥30 Kg/m², n (%)                 | 1,240 (23)          | 961 (25.8)     | 279 (16.8)     |              |         |             |
| Laboratory measures                  |                     |                |                |                |         |             |
| Fasting plasma glucose (mg/dL), mean (SD)|           | 77.3           | 120.1 (40.7)   | 120.1 (42.7)   | 120.1 (40.7) | 0.97    | 0.00*       |
| HbA1c (%), mean (SD)                 | 100                 | 68.4           | 6.8 (1.1)      | 6.8 (1.2)      | 6.8 (1.1) | 0.50    | 0.00*       |
| HDL-cholesterol (mg/dL), mean (SD)   | 100                 | 70.4           | 49.1 (14.3)    | 50.4 (14.7)    | 45.3 (12.4) | <0.01 | 0.38*       |
| Total cholesterol (mg/dL), mean (SD) | 100                 | 76.6           | 168.5 (37.8)   | 173.5 (37.9)   | 154.7 (34) | <0.01 | 0.52*       |
| LDL-cholesterol (mg/dL), mean (SD)   | 100                 | 70.1           | 95.6 (31)      | 98.2 (31.6)    | 88.2 (27.9) | <0.01 | 0.33*       |
| Triglycerides (mg/dL), mean (SD)     | 100                 | 75.2           | 125.2 (61.8)   | 130.8 (63.6)   | 109.5 (53.6) | <0.01 | 0.36*       |
| Albumin (g/dL), mean (SD)            | 100                 | 46             | 3.9 (0.4)      | 3.8 (0.4)      | 3.94 (0.5) | <0.01 | 0.13*       |
| Creatinine, mg/dL, mean (SD)         | 100                 | 76.4           | 1.00 (0.4)     | 0.96 (0.4)     | 1.19 (0.5) | <0.01 | 0.51*       |
| eGFR <60 mL/min/1.73 m² (%)           | 100                 | 46.4           | 2650 (49.1)    | 2088 (52.1)    | 562 (40.2) | <0.01 | 0.10†       |

(Continued)
each previous criterion of evidence-based cardiovascular preventive therapies.

DISCUSSION

Life expectancy at 90 years of age is only a few years and is almost equal in men and women (6.6 years in men and 7.9 years in women, at 85 years and over, according to Eurostat data for Spain), with lower gender differences in mortality rates for coronary heart diseases after 75 years. Therefore, it is reasonable to think that at 90 years or over, there would be fewer gender differences in cardiovascular risk and physician-prescribed preventive treatments than at previous ages.

T2DM is accentuated in older people. In general, the prevalence of T2DM is higher among males than females in all age groups, except in persons aged ≥85 years. However, in our study, the prevalence of diabetes in nonagenarians remained significantly higher in males. This preponderance of T2DM in males is due to their visceral and hepatic fat, which is greater than that of females. The prevalence of T2DM among nonagenarians in other Spanish studies and European studies was lower in both males and females.

Furthermore, in the present study, as in other Spanish studies, the percentage of older people living in a nursing home was lower than in an unselected population of nonagenarians living in central and northern Europe, for two reasons. First, the prevalence of dementia (13.3%) was lower in previous studies in older persons, probably owing to the association between adherence to a Mediterranean diet (widespread in southern Europe) and slower cognitive decline and lower risk of dementia.

### Table 1

| Use of                                      | Available values, % | All       | Females  | Males    | P value | Effect size |
|---------------------------------------------|---------------------|-----------|----------|----------|---------|-------------|
| Use of                                      |                     |           |          |          |         |             |
| Diuretics, n (%)                            | 100                 | 5520 (47.4)| 4139 (48.7)| 1381 (44)| <0.01   | 0.04†       |
| Antiplatelet agents, n (%)                  | 100                 | 5279 (45.3)| 3770 (44.3)| 1509 (48.1)| <0.01  | 0.03†       |
| Anticoagulants, n (%)                       | 100                 | 2536 (21.8)| 1801 (21.2)| 735 (23.4)| 0.01   | 0.02†       |
| Beta-blockers, n (%)                        | 100                 | 2312 (19.9)| 1639 (19.3)| 673 (21.4)| 0.01   | 0.02†       |
| Calcium antagonists (%)                     | 100                 | 3101 (26.6)| 2359 (27.7)| 742 (23.6)| <0.01  | 0.04†       |
| ACEI or ARB (%)                             | 100                 | 5135 (44.1)| 3765 (44.3)| 1370 (43.7)| 0.56   | 0.01†       |
| Statins, n (%)                              | 100                 | 4776 (41) | 3420 (40.2)| 1356 (43.2)| <0.01  | 0.03†       |
| Primary prevention (n=8043), n (%)          | 100                 | 2795 (34.8)| 2175 (35.4)| 620 (32.6)| 0.03   | 0.03†       |
| Secondary prevention (n=3602), n (%)        | 100                 | 1981 (55)| 1245 (52.7)| 736 (59.4)| <0.01  | 0.06†       |
| Oral antidiabetic drugs, n (%)              | 100                 | 6086 (52.3)| 4371 (51.4)| 1715 (54.7)| <0.01  | 0.04†       |
| Insulin, n (%)                              | 100                 | 1332 (11.4)| 1027 (12.1)| 305 (9.7)| <0.01  | 0.04†       |
| Oral antidiabetic drugs+Insulin, n (%)      | 100                 | 1352 (11.6)| 968 (11.4)| 384 (12.2)| <0.01  | 0.04†       |

*Cohen’s d.
†Cramer’s V.
ACEI, ACE inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, haemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure.

Figure 1 Proportion of nonagenarians with type 2 diabetes mellitus, free of cardiovascular events, who meet LDL-cholesterol goal, stratified by use of statins. LDL, low-density lipoprotein.
Figure 2  Proportion of nonagenarians with type 2 diabetes mellitus, on secondary prevention, who meet LDL-cholesterol goal, stratified by use of statins. LDL, low-density lipoprotein.

Second, as a result of the low supply of public nursing homes (free of charge from regional health services), the lack of family income to pay for private nursing homes, and the ability of families, friends, neighbours and other community-based caregivers to provide support, family and social support is more common in Spain than in other countries in the Organisation for Economic Co-operation and Development.

The prevalence of coronary artery disease and peripheral artery disease were lower in females than in males, as reported in other studies both in Spain and elsewhere. The sex differences in atherosclerotic disease in middle and advanced age are not yet completely understood. A possible explanation is that smoking is more prevalent in males, and this is a known risk factor for coronary artery disease and peripheral artery disease. We agree with other authors that diabetes in females aged less than 60 years is more strongly associated with myocardial infarction than the presence of diabetes in females over the age of 60 years. On the other hand, diabetes attenuates the protective effect of female sex and increases the incidence of cardiovascular events to the extent that is more pronounced than in males. The Framingham Heart Study and the Framingham Offspring Study (follow-up of 20 years) found that the adjusted HR for coronary artery disease mortality among diabetic people free of prior coronary artery disease was higher in females than in males (3.8 (95% CI 2.2 to 6.6) vs 2.1 (95% CI 1.3 to 3.3)). Survival has long been poorer in diabetic females than in diabetic males at 28 days and 1 year after myocardial infarction, probably owing to disparities between females and males in terms of cardiac procedures. Our findings could be explained by a probable survival bias: at 90 years of age, fewer females than males would have survived after previously having a myocardial infarction. Nevertheless, Vaccarino et al showed that the odds of death were 11.1% greater for females than for males with every 5-year decrease in age (95% CI 10.1% to 12.1%).

As in the present study, prior investigations have shown that from the sixth decade of life, diabetic females have a worse risk profile associated with cardiovascular disease and achieve fewer treatment targets for HbA1c, LDL-C, high-density lipoprotein cholesterol (HDL-C) and systolic blood pressure, even after controlling for age, body mass index and medication use.

The discordance between poorer control of lipids and blood pressure in women and less coronary artery disease and peripheral artery disease is a paradoxical phenomenon. There are various possible explanations for this issue: first, abdominal fat accumulation, which is more prevalent in males, is associated with cardiovascular risk factors, such as diabetes, hypertension and dyslipidaemia. It is also linked with all-cause and cardiovascular mortality in the elderly aged ≥80 years, thus partly explaining the lower presence of vascular complications in women. Second, as previously commented, numerous studies carried out in the cardiovascular field showed poorer use of diagnostic procedures when evaluating ischaemic heart disease and peripheral arterial disease in women. This issue may be due to gender bias in the manifestation of symptoms of ischaemia. In addition, clinicians may evaluate these symptoms without resorting to invasive tests that confirm the diagnosis and therefore to undertreatment.

In Spain, a cross-sectional study of 286,791 patients with T2DM aged 31–90 years showed a similar degree of control between males and females for HbA1c <7%, HbA1c <8%, systolic blood pressure <130 mm Hg and systolic blood pressure <140 mm Hg. However, findings were worse for LDL-C <130 mg/dL and LDL-C <100 mg/dL in females than in males.

Poorer adherence to evidence-based cardiovascular preventive therapies in women than in men is compatible with a low prevalence of coronary artery disease and peripheral artery disease, as described in another Spanish study with similar methodology.

Despite the time with T2DM, the proportion of subjects in our study who met their ABC goals was low, although similar to that reported in other studies with younger patients with T2DM. Rawshani et al recently found that patients with T2DM who had five risk factors within the
Table 2  Achievement goals of 11,645 nonagenarians living with T2DM, stratified by presence of dementia and type of prevention (primary or secondary)

|                         | Available values (%) | All            | Females       | Males          | P value |
|-------------------------|----------------------|----------------|---------------|----------------|---------|
| HbA1c <7%, n (%)        | 68.4                 | 5129 (64.4)    | 3779 (64.7)   | 1350 (63.6)    | 0.36    |
| Dementia (n=1550), n (%)| 63.6                 | 647 (65.6)     | 523 (67.1)    | 124 (59.9)     | <0.01   |
| Without dementia (n=10095), n (%) | 69.1     | 4482 (64.3)    | 3256 (64.3)   | 1226 (66.4)    | 0.80    |
| Primary prevention (n=8043), n (%) | 72          | 3590 (65.4)    | 2745 (65.1)   | 845 (66.1)     | 0.54    |
| Secondary prevention (n=3602), n (%) | 74.1     | 1539 (62.4)    | 1034 (63.6)   | 505 (59.9)     | 0.07    |
| HbA1c <8%, n (%)        | 68.4                 | 6860 (86.2)    | 5012 (85.8)   | 1848 (87.1)    | 0.15    |
| Dementia (n=1550), n (%)| 63.6                 | 847 (85.9)     | 670 (86)      | 177 (85.5)     | 0.85    |
| Without dementia (n=10095), n (%) | 69.1     | 6013 (86.2)    | 4342 (85.8)   | 1671 (87.3)    | 0.12    |
| Primary prevention (n=8043), n (%) | 72          | 4760 (62.4)    | 3631 (63.6)   | 1129 (68.3)    | 0.05    |
| Secondary prevention (n=3602), n (%) | 74.1     | 2100 (85.1)    | 1381 (85)     | 719 (85.3)     | 0.84    |
| BP <130/80 mm Hg, n (%) | 72.6                 | 3118 (36.9)    | 2169 (35.7)   | 949 (39.9)     | <0.01   |
| Primary prevention (n=8043), n (%) | 72          | 2067 (35.7)    | 1511 (34.6)   | 556 (39.1)     | <0.01   |
| Secondary prevention (n=3602), n (%) | 74.1     | 1051 (39.4)    | 658 (38.5)    | 393 (40.9)     | 0.22    |
| BP <140/85 mm Hg, n (%)† | 72.6  | 5413 (64)      | 3808 (62.7)   | 1605 (67.4)    | <0.01   |
| Primary prevention (n=8043), n (%) | 72          | 3648 (63)      | 2701 (61.9)   | 947 (66.6)     | <0.01   |
| Secondary prevention (n=3602), n (%) | 74.1     | 1765 (66.2)    | 1107 (64.9)   | 658 (68.5)     | 0.05    |
| BP <140/90 mm Hg, n (%)‡ | 72.6         | 5521 (65.3)    | 3888 (64)     | 1633 (66.6)    | <0.01   |
| Primary prevention (n=8043), n (%) | 72          | 3730 (63.4)    | 2762 (63.2)   | 968 (68.1)     | <0.01   |
| Secondary prevention (n=3602), n (%) | 74.1     | 1791 (67.2)    | 1126 (66)     | 665 (69.3)     | 0.08    |
| LDL-cholesterol <130 mg/dL, n (%) | 70.1 | 7078 (86.7)    | 5100 (84.8)   | 1978 (91.8)    | <0.01   |
| Primary prevention (n=8043), n (%) | 70          | 4800 (85.3)    | 3634 (83.8)   | 1166 (90.2)    | <0.01   |
| Secondary prevention (n=3602), n (%) | 70.1      | 2278 (89.7)    | 1466 (87.4)   | 812 (94.2)     | <0.01   |
| LDL-cholesterol <100 mg/dL, n (%) | 70.1 | 4828 (59.1)    | 3343 (55.6)   | 1485 (68.9)    | <0.01   |
| Primary prevention (n=8043), n (%) | 70          | 3113 (55.3)    | 2287 (52.8)   | 826 (63.9)     | <0.01   |
| Secondary prevention (n=3602), n (%) | 70.1      | 1715 (67.5)    | 1056 (62.9)   | 659 (76.5)     | <0.01   |
| LDL-cholesterol <70 mg/dL, n (%)§ | 70.1 | 27 (16.7)      | 674 (15.6)    | 267 (20.6)     | <0.01   |
| Primary prevention (n=8043), n (%) | 70          | 941 (16.7)     | 674 (15.6)    | 267 (20.6)     | <0.01   |
| Secondary prevention (n=3602), n (%) | 70.1      | 751 (29.6)     | 444 (26.5)    | 307 (35.6)     | <0.01   |
| ABC goals: HbA1c <7% and BP <140/85 mm Hg and LDL-cholesterol <100 mg/dL, n (%) | 73.9 | 1529 (19.1)    | 1033 (17.3)   | 516 (24.2)     | <0.01   |
| Primary prevention (n=8043), n (%) | 73.9         | 993 (17.7)     | 691 (16)      | 302 (23.3)     | <0.01   |
| Secondary prevention (n=3602), n (%) | 74.1      | 556 (22.3)     | 342 (20.6)    | 214 (25.6)     | <0.01   |

*Recommendations of the Joint National Committee on Prevention Detection, Evaluation and Treatment of High Blood Pressure (2003).
†Recommendations of the European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension (2013).
‡Recommendations of the American Diabetes Association for older adults (2015).
§Recommendations of European Society of Cardiology guidelines on the management of diabetes developed in collaboration with the European Association for the Study of Diabetes for secondary prevention.

BP, blood pressure; HbA1c, haemoglobin A1c; LDL, low-density lipoprotein; T2DM, type 2 diabetes mellitus.

Target ranges (HbA1c, LDL-C, albuminuria, blood pressure and smoking) appeared to have little or no excess risk of death, myocardial infarction or stroke, compared with the general population. Importantly, the protection derived from control of risk factors occurred in a stepwise fashion, so that, for example, individuals who met two targets had better outcomes than those who met one target. Therefore, we believe it is necessary to improve the degree of control of ABC regardless of age.

As for therapeutic profile, our data show that females were taking oral antidiabetic drugs, antiplatelet agents, anticoagulants agents, statins, ACE inhibitors, beta-blockers and oral glucose-lowering drugs in a lower proportion than males. These results are coincident with...
those of other studies. In secondary prevention, the percentage of patients with poor control of LDL-C who were taking statins was similar for both sexes. However, in primary prevention and cases of poor control of LDL-C, statins were taken significantly more frequently by females.

In secondary prevention, men received statins more frequently than women. This circumstance highlights the inconsistency between available evidence and prescription under usual clinical conditions. Statins are effective in women for secondary prevention of cardiovascular disease and there is much doubt surrounding primary prevention in women at low to intermediate cardiovascular risk, so much so that the number needed to treat (NNT) to prevent one coronary heart disease event is 77 for men and 140 for women. However, for secondary prevention, the NNT is similar for men and women, around 25 for major coronary events.

Nevertheless, we found room for improvement in the use of statins. Approximately, a quarter of patients who take statins had an LDL-C reading from the previous year. This situation is less logical in secondary prevention, given that is not possible to know the effect of treatment and, therefore, adjust the dose. In the primary prevention, there is not enough evidence to support treatment. The differences between studies may be due, in part, to ethnic differences, unequal access to health resources, different priorities in the management of T2DM between countries, and disparities in the type of insurance (public or private) used to pay for treatment.

Treatment of hypertension was optimal in only half of the study patients. This finding clearly reveals an area for improvement, given that patients with diabetes and hypertension should be treated with ACE inhibitors or ARBs, especially if they have albuminuria.

Our study is subject to a series of limitations. First, its cross-sectional design prevents us from establishing causal relationships between variables. Second, many data are missing for variables such as blood pressure, body mass index, estimated glomerular filtration rate, albumin, HbA1c, HDL-C, LDL-C and fasting plasma glucose. However, it is important to remember that this study was carried out under real conditions of clinical practice, with little time per patient in a primary care office visit. Third, the duration of physician visits is similar across the age groups, and given that elderly patients have more comorbidities and are prescribed more medications than younger patients, they require specific monitoring and counselling, with the result that recording of variables in their clinical history may be poorer. Therefore, the quality of data collection is not comparable to that of studies based on controlled conditions, such as clinical trials. Although findings are consistent with those from previous studies, there may still be bias due to missing data. Lastly, data on the therapeutic profile were based on the drugs prescribed; therefore, we did not have data on adherence.

The main strength of the study is that it is based on all persons with diabetes in our region, thus preventing recruitment bias. In addition, data from real-life clinical practice in primary care increase the knowledge of health workers and healthcare policy-makers and make it possible to improve the clinical management of patients and reorient clinical practice.

In conclusion, our study revealed sex differences in nonagenarians with T2DM. These took the form of a higher prevalence of cardiovascular risk factors (hypertension, dyslipidaemia and obesity), significantly higher blood pressure and body mass index, and worse values in total cholesterol, LDL-C and triglycerides, albumin and estimated glomerular filtration rate in females than in males. Furthermore, females were less likely to achieve ABC goals, and the proportion of females treated with antiplatelet drugs, lipid-lowering drugs and oral glucose-lowering drugs was lower than that of males. Lastly, adherence to evidence-based cardiovascular preventive therapies was poorer among females. Our findings indicate that sex differences in younger patients with T2DM persist in patients aged ≥90 years and that there is considerable room for improvement in standards of preventive care in nonagenarians with T2DM, especially women.

---

### Table 3 Influence of comorbidity on adequate use of statins after adjusting for gender, age and dementia

| Comorbidity            | OR    | 95% CI     | P value |
|------------------------|-------|------------|---------|
| Charlson Index         | 0.83  | 0.76 to 0.92 | <0.01   |
| Male sex               | 1.27  | 0.90 to 1.79 | 0.18    |
| Age                    | 1.04  | 0.98 to 1.09 | 0.19    |
| Dementia               | 0.74  | 0.52 to 1.05 | 0.09    |

Among 1089 T2DM nonagenarians whose most recent LDL-cholesterol reading was ≥130 mg/dL, LDL, low-density lipoprotein; T2DM, type 2 diabetes mellitus.

---

### Table 4 Adherence to evidence-based cardiovascular preventive therapies by sex

| Therapy                          | All     | Females | Males | P value |
|----------------------------------|---------|---------|-------|---------|
| Hypertensive patients with albuminuria who were taking ACE inhibitors or ARBs, % | 42.4    | 39.1    | 50.4   | <0.01   |
| Patients with dyslipidaemia and prior cardiovascular events who were taking statins, % | 41.5    | 36.4    | 54.3   | <0.01   |
| Patients with prior cardiovascular events or chronic atrial fibrillation who were taking antithrombotic drugs, % | 86.3    | 85.9    | 87.2   | <0.01   |

ARBS, angiotensin II receptor blockers.
Acknowledgements This study was possible thanks to the physicians and nurses of the Madrid Primary Care Health Service, who provide optimal care to patients with diabetes.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study protocol was approved by the Research Ethics Committee of Ramón y Cajal Hospital in Madrid. The study complied with the International Guidelines for Ethical Review of Epidemiological Studies (Geneva, 1991).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as online supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES
1. WHO. Life expectancy [Internet]. 2016. Available: http://www.who.int/gho/mortality_burden_disease/life_tables/situation_trends/en/ [Accessed 23 Dec 2018].
2. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke; Statistics-2016 update: a report from the American heart association. Circulation 2016;133:e38–60.
3. DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003;26:61–9.
4. Yaffe K, Falvey C, Hamilton N, et al. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol 2012;69:1170–5.
5. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherothrombotic cardiovascular risk in adults: a report of the American College of Cardiology/American heart association Task force on practice guidelines. J Am Coll Cardiol 2014;63:2899–934.
6. Al-Omran M, Mamdani MM, Lindsay TF, et al. Suboptimal use of statin therapy in elderly patients with atherosclerosis: a population-based study. J Vasc Surg 2008;48:607–12.
7. O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2015;44:213–8.
8. Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 2014;57:1542–51.
9. Franch-Nadal J, Mata-Cases M, Vinagre I, et al. Differences in the cardiometabolic control in type 2 diabetes according to gender and the presence of cardiovascular disease: results from the eControl study. Int J Endocrinol 2014;2014:1437109.
10. Cambra K, Galbete A, Forga L, et al. Sex and age differences in the achievement of control targets in patients with type 2 diabetes: results from a population-based study in a South European region. BMC Fam Pract 2016;17:144.
11. Cabáuña-Martínez MJ, Cabrero-García J, Richard-Martínez M, et al. The Spanish versions of the Barthel index (BI) and the Katz index (KI) of activities of daily living (ADL): a structured review. Arch Gerontol Geriatr 2009;49:67–77.
12. Vergea I, Bilbao A, Orive M, et al. Validation of the Spanish version of the Lawton IADL scale for its application in elderly people. Health Qual Life Outcomes 2012;10:130.
13. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.
14. Lenfant C, Chobanian AV, Jones DW, et al. Seventh report of the joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7): resetting the hypertension goals. Hypertension 2003;41:1179–9.
15. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 2014;23:3–16.
16. American Diabetes Association. (10) Older adults. Diabetes Care 2015;38 Suppl:S67–9.
17. Chamberlain JJ, Johnson EL, Leal S, et al. Cardiovascular disease and risk management: review of the American diabetes association standards of medical care in diabetes 2018. Ann Intern Med 2018;168:640.
18. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. air Force/Texas coronary atherosclerosis prevention study. JAMA 1998;279:1615–22.
19. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 2002;289:2998–3007.
20. Neil HAW, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65–75 years at randomization: collaborative atorvastatin diabetes study (cards). Diabetes Care 2006;29:2378–84.
21. Nakaya N, Mizuno K, Ohashi Y, et al. Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study). Drugs Aging 2011;28:881–92.
22. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–58.
23. Lemaire RN, Psaty BM, Heckbert SR, et al. Therapy with hydroxy methylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the cardiovascular health study. Arch Intern Med 2002;162:1395–400.
24. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (prosper): a randomised controlled trial. Lancet 2002;360:1623–30.
25. Glynn RJ, Koening W, Nordstedtgaard BA, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 2010;152:W174:488–96.
26. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACC secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American heart association and American College of cardiology Foundation endorsed by the world heart Federation and the preventive cardiovascular nurses association. J Am Coll Cardiol 2011;58:2432–46.
27. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial:

Salinero-Fort MA, et al. BMJ Open 2019;9:e030344. doi:10.1136/bmjopen-2019-030344

9

BMJ Open: first published as 10.1136/bmjopen-2019-030344 on 20 September 2019. Downloaded from http://bmjopen.bmj.com/ on September 18, 2023 by guest. Protected by copyright.
factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. *BMJ* 2008;337:a1840.

28. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. *JAMA* 2008;300:2134–41.

29. Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. *N Engl J Med* 2018;379:1529–39.

30. de Burgos-Lunar C, Salinero-Fort MA, Cárdenas-Valladolid J, et al. Validation of diabetes mellitus and hypertension diagnosis in computerized medical records in primary health care. *BMJ Res Methodol* 2011;11:146.

31. Gil Montalbán E, Ortiz Marrón H, López-Gay Lucio-Villegas D, et al. [Validity and concordance of electronic health records in primary care (AP-Madrid) for surveillance of diabetes mellitus. PREMIDERC study]. *Gac Sanit* 2014;28:393–6.

32. Eurostat. Life expectancy by age and sex [Internet]. 2019. Available: http://appsso.eurostat.ec.europa.eu/nui/substituteViewTableAction.do. [Accessed 08 May 2019].

33. Bots SH, Peters SAE, Woodward M. Sex differences in coronary heart disease and stroke mortality: a global assessment of the effect of ageing between 1980 and 2010. *BMJ Glob Health* 2017;2:e000298.

34. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004;27:1047–53.

35. Geer EB, Shen W. Gender differences in insulin resistance, body composition, and insulin sensitivity. *Obes Rev* 2008;9(Suppl 1):90–75.

36. Ferrer Feliu A, Formiga F, Henriquez E, et al. Evaluación funcional Y cognitiva En Una población Urbana de mayores de 89 años. Estudio NonaSantFeliu. *Revista Española de Geriatría y Gerontología* 2006;41:21–6.

37. Lisso J, Tainea K, Stenhom S, et al. Body mass index, waist circumference, and waist-to-hip ratio as predictors of mortality in nonagenarians: the vitality 90+ study. *J Gerontol A Biol Sci Med Sci* 2011;66:1244–50.

38. Singer M, Conde-Martel A, Hemmersbach-Miller M, et al. Mortality hospital of nonagenarian patients in internal medicine. *Rev Clin Esp* 2018;218:61–5.

39. Zunzunegui MV, Béland F, Otero A. Support from children, living arrangements, self-rated health and depressive symptoms of older people in Spain. *Int J Epidemiol* 2001;30:1090–9.

40. Nosraty L, Sarkeial T, Hervonen A, et al. Is there successful aging for nonagenarians? the vitality 90+ study. *J Aging Res* 2012;2012:868797.

41. Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the cognitive function and ageing study I and II. *Lancet* 2013;382:1405–12.

42. Lourida I, Soni M, Thompson-Coon J, et al. Mediterranean diet, cognitive function, and dementia: a systematic review. *Epidemiol Aging* 2013;24:679–89.

43. Tomiak M, Berthelot JM, Guimond E, et al. Factors associated with nursing-home entry for elders in Manitoba, Canada. *J Gerontol A Biol Sci Med Sci* 2000;55:M279–87.

44. Vinagre I, Mata-Cases M, Herrmosilla E, et al. Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain). *Diabetes Care* 2012;35:774–9.

45. Penno G, Solini A, Bonora E, et al. Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study. *J Intern Med* 2013;274:176–91.

46. Campbell DJ. Why do men and women differ in their risk of myocardial infarction? *Eur Heart J* 2008;29:835–6.

47. LaRosa JC, He J, Vuppuru S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. *JAMA* 1999;282:2340–6.

48. de Boer IH, Bangalore S, Benetos A, et al. Diabetes and hypertension: a position statement by the American diabetes association. *Diabetes Care* 2017;40:1273–84.

49. Lo A, Ryder K, Shorr RI. Relationship between patient age and duration of physician visit in ambulatory setting: does one size fit all? *J Am Geriatr Soc* 2005;53:1162–7.